Drug Therapy After Implant

B ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening. Scand J Rheumatol 32:287–294

Huiskes R, Weinans H, van Rietnbergen B (1992) The relationship between stress shielding and bone resorption around total hip stem and the effects of flexible materials. Clin Ortop Relat Res 274:124–134

Taylor AF, Saunders MM, Shingle DL et al (2007) Mechanically stimulated osteocytes regulate osteoblastic activity via gap junctions. Am J Physiol Cell Physiol 292:545–552CrossRef

Moustafa A, Sugiyama T, Saxon LK et al (2009) The mouse fibula as a suitable bone for the study of functional adaptation to mechanical loading. Bone 44:930–935PubMedCentralPubMedCrossRef

Nunley RM, La Valle CJ, Barrack RI (2009) Is patient selection important for hip resurfacing? Clin Orthop Relat Res 467:56–65PubMedCentralPubMedCrossRef

Whang ML, Sharkeyv PF, Tuan RS (2004) Particle bioreactivity and wear-mediated osteolysis. J Arthroplasty 19:1028–1038CrossRef

Manley MT, D’Antonio JA, Capello WN et al (2002) Osteolysis: a disease of access to fixation interfaces. Clin Orthop Relat Res 405:129–137PubMedCrossRef

10.

Fleisch H (2000) Bisphosphonates in bone disease. From the laboratory to the patient. Academic Press, San Diego USA–London UK, p 40

11.

Rodan GA, Fleisch HA (1996) Bisphosphonates: mechanisms of action. J Clin Invest 97(12):2692–2696PubMedCentralPubMedCrossRef

12.

Shanbhag AS, Hasselman CT, Rubash HE (1997) Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop Rel Res 44:33–43

13.

Millet PJ, Allen MJ, Bostrom MP (2002) Effects of alendronate on particle-induced osteolysis in a rat model. J Bone Joint Surg 84A:236–249

14.

Astrand J, Aspenberg P (1999) Alendronate did not inhibit instability-induced bone resorption. A study in rats. Acta Orthop Scand 70:67–70PubMedCrossRef

15.

Huk O, Zukor DJ, Antoniou J et al (2003) Effect of pamidronate on stimulation of macrophage TNF-α release by ultra-high-molecular-weight polyethylene particle: a role for apoptosis. J Orthop Res 21:81–87PubMedCrossRef

16.

Horowitz SM, Algan SA, Purdon MA (1996) Pharmacological inhibition of particulate-induced bone resorption. J Biomed Mater Res 31:91–96PubMed PubMedCrossRef

18.

Peter B, Pioletti DP, Laib S et al (2005) Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone 36:52–60PubMedCrossRef

19.

Suratwala SJ, Cho SK, van Raalte JJ et al (2008) Enhancement of periprosthetic bone quality with topical hydroxypatite-bisphosphonate composite. J Bone Joint Surg Am 90(10):2189–2196PubMedCentralPubMedCrossRef

20.

Liberman UA, Weiss SR, Broöll J, Minne HV et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443PubMedCrossRef

21.

Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Interv Trial Res. Lancet 348:1541–1553

22.

Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280(333):2077–2082PubMed

Only gold members can continue reading. Log In or Register to continue